-+ 0.00%
-+ 0.00%
-+ 0.00%

Chemomab Therapeutics Q3 2026 net loss triples year over year to $5.1 million

PUBT·11/19/2026 13:03:39
Diffusion vocale
Chemomab Therapeutics Q3 2026 net loss triples year over year to $5.1 million
  • Chemomab Therapeutics’ third-quarter 2026 net loss tripled year over year to $5.1 million.
  • R&D expenses more than tripled year over year to $3.7 million, primarily due to recognition of prepaid manufacturing costs.
  • Cash, cash equivalents and short-term bank deposits fell 30% from June 30 to $4.7 million at September 30, 2026.
  • The proposed Scipher Medicine merger is expected to close in the first quarter of 2027, subject to shareholder approval and closing conditions.
  • Following closing, the combined company plans to initiate a Phase 2 nebokitug rheumatoid arthritis trial in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190800PRIMZONEFULLFEED9881129) on November 19, 2026, and is solely responsible for the information contained therein.